Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
GLOBETECH PUBLISHING
FOCUS DIAGNOSTICS, INC.

OGT Enters Licensing Agreement for Twelve Colorectal Cancer Biomarkers

By Labmedica International staff writers
Posted on 27 Feb 2012
Oxford Gene Technology (OGT; Oxford, United Kingdom), provider of clinical genetics and diagnostic solutions, has entered into an exclusive licensing agreement with Inven2 (Oslo, Norway), the technology transfer office at Oslo University Hospital (OUS; Oslo, Norway) and University of Oslo (UiO; Oslo, Norway), for 12 promising colorectal cancer tissue biomarkers.

The DNA methylation biomarkers were developed in the laboratory of Prof. Ragnhild A. Lothe, in the department of Cancer Prevention, the Norwegian Radium Hospital, part of the Oslo University Hospital. As a result of the agreement OGT will be able to commercialize any test developed using these biomarkers and to sublicense the markers to other parties.

The results obtained in Prof. Lothe’s laboratory were validated by OGT, and demonstrated a sensitivity of 93% and specificity of 90% when using tissue biopsies. The efficacy of the biomarkers in blood and fecal samples is still being studied.

“This licensing agreement gives OGT exclusive access to genetic markers which are associated with colorectal cancer,” stated Dr. Mike Evans, CEO, of OGT. “We believe that developing tests that include these genetic markers will permit the earlier identification of patients at risk of this disease and allow for more timely diagnosis and clinical interventions.” Dr. Evans added, “The higher specificity of this new panel of markers could provide a more robust screening tool than the tests currently used, while eventually lowering overall costs, which would be of significant benefit for both patients and the clinicians using them.”

A robust preventive strategy for colorectal cancer that can stratify patients into appropriate screening or surveillance programs is lacking for early detection of cancer. Internationally, the chosen modality of colorectal cancer screening varies, with cost and availability of diagnostic resources likely to be the leading factors effecting program design.

OGT provides clinical genetics and diagnostic solutions to advance molecular medicine. The company supplies specific customized biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.

Related Links:
Oxford Gene Technology
Inven2
University of Oslo


Sekisui Diagnostics
VIRCELL
DiagCor Bioscience
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: The URiSCAN Super Plus reflectance meter (Photo courtesy of YD Diagnostics).

Semiquantitative Urine Dipstick Evaluated for Microalbuminuria Screening

The urine microalbumin test is used as a screening test for the diagnosis of renal complications in diseases, such as diabetic nephropathy, cardiovascular disease, and hypertension. A urine dipstick... Read more

Microbiology

view channel
Image: The adult free-living female Strongyloides stercoralis with a row of eggs within the body of the nematode (Photo courtesy of the CDC - Centers for Disease Control and Prevention).

Rapid Serological Assay Developed for Strongyloidiasis

Several imperfect methods exist for diagnosing strongyloidiasis and stool examination with microscopic identification of larvae considered the gold standard diagnostic procedure, showing good specificity... Read more

Pathology

view channel
Image: The BD Viper LT System for fully automated, integrated molecular testing on a table top analyzer (Photo courtesy of BD Diagnostics).

Modern Methods Accurately Detects Cervical Cancer

The newer Papanicolaou test (Pap tests) and human papilloma virus (HPV) screening more accurately identify precancerous cellular changes that potentially develop into cervical cancer. Compared to a... Read more

Lab Tech.

view channel
Image: RNAscope detects TP63 mRNA expression in human prostate tissue (Photo courtesy of Advanced Cell Diagnostics).

RNA Biomarker Assay Now Manufactured According to Strict ISO Regulatory Criteria

A line of diagnostic kits that measures RNA biomarkers with single-molecule sensitivity is now being manufactured under the stringent requirements of ISO 13485:2003 certification. Advanced Cell Diagnostics, Inc.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.